The DOI matches its Crossref record; 73 of the 79 references it cites were found in a registry or an index.
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Open accessAbstract
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 1 million deaths in the first 6 months of the pandemic and huge economic and social upheaval internationally. An efficacious vaccine is essential to prevent further morbidity and mortality. Although some countries might deploy COVID-19 vaccines on the strength of safety and immunogenicity data alone, the goal of vaccine development is to gain direct evidence of vaccine efficacy in protecting humans against SARS-CoV-2 infection and COVID-19 so that manufacture of efficacious vaccines can be selectively upscaled. A candidate vaccine against SARS-CoV-2 might act against infection, disease, or transmission, and a vaccine capable of reducing any of these elements could contribute to disease control. However, the most important efficacy endpoint, protection against severe disease and death, is difficult to assess in phase 3 clinical trials. In this Review, we explore the challenges in assessing the efficacy of candidate SARS-CoV-2 vaccines, discuss the caveats needed to interpret reported efficacy endpoints, and provide insight into answering the seemingly simple question, "Does this COVID-19 vaccine work?"
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the long-term risks and benefits of a SARS-CoV-2 vaccine will take a long time to fully evaluate in adults33 while the public health needs of a vaccine are pressing.”
From SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges (2021) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Prevalence of Asymptomatic SARS-CoV-2 Infection
Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,348
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Research works printed but not linked: 1
- Yu, 2020, DNA vaccine protection against SARS-CoV-2 in rhesus macaques, Science, 369, 806, 10.1126/science.abc6284 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 633
Yuan, H., Chen, P., Wan, C., Li, Y., & Liu, B. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116814 · Cited by 35
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Abhyankar, M. M., Mann, B. J., Sturek, J. M., Brovero, S. G., Moreau, G. B., Sengar, A., Richardson, C. M., Agah, S., Pomés, A., Kasson, P. M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00399-0 · Cited by 32
Wu, J., Xu, D., Li, Q., Tarimo, C. S., Wang, M., Gu, J., Wei, W., Zhang, X., Huang, Y., Ma, M., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.038 · Cited by 32
Antonelli, M., Pujol, J. C., Chaudhari, A., Granerød, J., Canas, L. S., Graham, M. S., Kläser, K., Marc Modat, A., Molteni, E., Murray, B. A. K., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.02.015 · Cited by 32
Vaccinations in multiple sclerosis patients receiving disease-modifying drugs
Otero‐Romero, S., Ascherio, A., & Lebrun‐Frénay, C. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000929 · Cited by 32
Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach
Martínez‐Rodríguez, D., González‐Parra, G., & Villanueva, R. J. (2021) · Epidemiologia · doi:10.3390/epidemiologia2020012 · Cited by 32
Bonanni, P., Cantón, R., Gill, D., Halfon, P., Liebert, U. G., Crespo, K. A. N., Martín, J. J. P., & Trombetta, C. M. (2021) · COVID · doi:10.3390/covid1010004 · Cited by 36
Bouillon, K., Baricault, B., Botton, J., Jabagi, M.-J., Bertrand, M., Semenzato, L., Le Vu, S., Drouin, J., Dray-Spira, R., Weill, A., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000104 · Cited by 31
Mathematical Modeling of COVID-19 Dynamics under Two Vaccination Doses and Delay Effects
Sepulveda, G., Arenas, A. J., & González‐Parra, G. (2023) · Mathematics · doi:10.3390/math11020369 · Cited by 31
Bari, E., Ferrarotti, I., Saracino, L., Perteghella, S., Torre, M. L., Richeldi, L., & Corsico, A. G. (2021) · Cells · doi:10.3390/cells10051203 · Cited by 29
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Biswas, M., Sawajan, N., Rungrotmongkol, T., Sanachai, K., Ershadian, M., & Sukasem, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835136 · Cited by 31
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429759 · Cited by 29
Alencar, C. H., Cavalcanti, L. P. D. G., de Almeida, M. M., Barbosa, P. P. L., Cavalcante, K. K. D. S., de Melo, D. N., Alves, B. C. F. D. B., & Heukelbach, J. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6030129 · Cited by 30
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
Rowntree, L. C., Chua, B. Y. L., Nicholson, S. R., Koutsakos, M., Hensen, L., Douros, C., Selva, K. J., Mordant, F. L., Wong, C. Y., Habel, J. R., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1258 · Cited by 29
Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials
Marsh, A. A., Magalhães, M., Peeler, M., Rose, S., Darton, T. C., Morrison, J., Peeler, M., Shah, S. K., & Schmit, V. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275823 · Cited by 34
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
Buttari, F., Bruno, A., Dolcetti, E., Azzolini, F., Bellantonio, P., Centonze, D., & Fantozzi, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102983 · Cited by 28
Predicting physical distancing over time during COVID-19: testing an integrated model
Hagger, M. S., Smith, S. R., Keech, J. J., Moyers, S. A., & Hamilton, K. (2021) · Psychology and Health · doi:10.1080/08870446.2021.1968397 · Cited by 30
Jiang, N., Gu, P., Liu, K., Song, N., & Jiang, X. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2013077 · Cited by 28
Parental coronavirus disease vaccine hesitancy for children in Bangladesh: a cross-sectional study
Ali, M., Ahmed, S. M. G., Bonna, A. S., Sarkar, A.-S., Islam, M. A., Urmi, T. A., & Proma, T. S. (2022) · F1000Research · doi:10.12688/f1000research.76181.1 · Cited by 30
Bouwmans, P., Messchendorp, A. L., Sanders, J., Hilbrands, L. B., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., ten Dam, M. A., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02680-3 · Cited by 27
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 29
Effectiveness of COVID-19 Vaccination on Transmission: A Systematic Review
Oordt-Speets, A. M., Spinardi, J., Mendoza, C., Yang, J., Morales, G., McLaughlin, J. M., & Kyaw, M. H. (2023) · COVID · doi:10.3390/covid3100103 · Cited by 33
IgG and IgA Antibodies Post SARS-CoV-2 Vaccine in the Breast Milk and Sera of Breastfeeding Women
Scrimin, F., Campisciano, G., Comar, M., Ragazzon, C., Davanzo, R., Quadrifoglio, M., Giangreco, M., Stabile, G., & Ricci, G. (2022) · Vaccines · doi:10.3390/vaccines10010125 · Cited by 27
COVID-19-Related Brain Injury: The Potential Role of Ferroptosis
Zhang, R., Sun, C., Chen, X., Han, Y., Zang, W., Jiang, C., Wang, J., & Wang, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s353467 · Cited by 27
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
Blasi, F., Gramegna, A., Sotgiu, G., Saderi, L., Voza, A., Aliberti, S., & Amati, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106355 · Cited by 27
Rani, M. D. M., Mohamed, N. A., Solehan, H. M., Ithnin, M., Ariffien, A. R., & Isahak, I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269059 · Cited by 26
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop
Williams, E., Craig, K. J., Chiu, C., Davies, H. T., Ellis, S., Emerson, C., Jamrozik, E., Jefford, M. L., Kang, G., Kapulu, M. C., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.004 · Cited by 25
The Impact of the SARS-CoV-19 Pandemic on the Global Gross Domestic Product
Korneta, P., & Rostek, K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105246 · Cited by 25
Murugan, C., Ramamoorthy, S., Kuppuswamy, G. P., Murugan, R. K., Sivalingam, Y., & Sundaramurthy, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.144 · Cited by 28
Social Media, Public Health, and Community Mitigation of COVID-19: Challenges, Risks, and Benefits
Basch, C. H., Basch, C. E., Hillyer, G. C., & Meleo-Erwin, Z. C. (2022) · Journal of Medical Internet Research · doi:10.2196/36804 · Cited by 27
Modelling: Understanding pandemics and how to control them
Marion, G., Hadley, L., Isham, V. S., Mollison, D., Panovska‐Griffiths, J., Pellis, L., Tomba, G. S., Scarabel, F., Swallow, B., Trapman, P., et al. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100588 · Cited by 29
Lin, Y., Shao, Y., Liu, Y., Yang, R., Liao, S., Yang, S., Xu, M., & He, J. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2105233 · Cited by 26
Understanding the mechanisms for COVID-19 vaccine’s protection against infection and severe disease
Yang, H., Xie, Y., & Li, C. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2174529 · Cited by 25
Calabrò, G. E., Pappalardo, C., D’Ambrosio, F., Vece, M., Lupi, C., Lontano, A., Russo, M. D., Ricciardi, R., & de Waure, C. (2023) · Vaccines · doi:10.3390/vaccines11051011 · Cited by 27
Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
Anthony, D. P. S., Sivakumar, K., Venugopal, P., Sriram, D. K., & George, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01022-9 · Cited by 23
Imai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 21
Qin, N., Shi, S., Duan, Y., Ma, G., Li, X., Shen, Z., Zhang, S., Luo, A., & Zhong, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.754904 · Cited by 26
Modelling the COVID-19 epidemic and the vaccination campaign in Italy by the SUIHTER model
Parolini, N., Dede’, L., Ardenghi, G., & Quarteroni, A. M. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.03.002 · Cited by 29
Mulamba, C., Williams, C., Kreppel, K. S., Ouédraogo, J., & Olotu, A. (2022) · Malaria Journal · doi:10.1186/s12936-022-04173-y · Cited by 27
Wei, Q., Liu, S., Huang, X., Xin, H., & Ding, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.11.002 · Cited by 24
Therapeutic approaches for SARS-CoV-2 infection
Gupta, A., Pradhan, A., Maurya, V. K., Kumar, S., Theengh, A., Puri, B., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.04.026 · Cited by 23
The future of COVID-19: A vaccine review
Vashi, A. P., & Coiado, O. C. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.08.011 · Cited by 23
Molecular modeling of the interaction of ligands with ACE2–SARS-CoV-2 spike protein complex
Isaac-Lam, M. F. (2021) · In Silico Pharmacology · doi:10.1007/s40203-021-00114-w · Cited by 24
Wong, L. P., Alias, H., Tan, Y. R., & Tan, K. M. (2021) · International Journal of Older People Nursing · doi:10.1111/opn.12436 · Cited by 24
S100A8 may govern hyper‐inflammation in severe COVID‐19
Deguchi, A., Yamamoto, T., Shibata, N., & Maru, Y. (2021) · The FASEB Journal · doi:10.1096/fj.202101013 · Cited by 24
Kantarcıoğlu, B., Iqbal, O., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Ligocki, M. A., Jeske, W. P., Adıgüzel, C., Gerotziafas, G., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211056648 · Cited by 25
González‐Parra, G., Cogollo, M. R., & Arenas, A. J. (2022) · Axioms · doi:10.3390/axioms11030109 · Cited by 22
Capponi, M., Pulvirenti, F., Cinicola, B. L., Brindisi, G., Conti, M. G., Colaiocco, G., Castro, G. D., Guido, C. A., Duse, M., Midulla, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10071056 · Cited by 21
Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
Huang, C., Jang, T., Wu, P., Kuo, M., Yeh, M., Wang, C., Liang, P., Wei, Y., Hsu, P., Huang, C., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02056-5 · Cited by 25
Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2
Stoddard, M., Sarkar, S., Lin, Y., Nolan, R. P., White, D. E., White, L. F., Hochberg, N. S., & Chakravarty, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254734 · Cited by 21
Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
Labarrere, C. A., & Kassab, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652252 · Cited by 22
Majcherek, M., Matkowska‐Kocjan, A., Szymczak, D., Karasek, M., Szeremet, A., Kiraga, A., Milanowska, A., Kuźnik, E., Kujawa, K., Wróbel, T., et al. (2022) · Cancers · doi:10.3390/cancers14020325 · Cited by 21
Wu, J., Ma, M., Miao, Y., Ye, B., Li, Q., Tarimo, C. S., Wang, M., Gu, J., Wei, W., Zhao, L., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.796467 · Cited by 21
Xie, T., Lu, S., He, Z., Liu, H., Wang, J., Tang, C., Yang, T., Yu, W., Li, H., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00920-4 · Cited by 20
Wong, E. L., Qiu, H., Chien, W. T., Wong, J. C.-L., Chalise, H. N., Hoang, H. T.-X., Nguyen, H. T., Chan, P. K. S., Wong, M. C. S., Cheung, A. W.-L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.28061 · Cited by 21
Pu, Y., Chen, L., He, X., Ma, Y., Cao, J., & Jiang, W. (2023) · Food Innovation and Advances · doi:10.48130/fia-2023-0006 · Cited by 21
Vaccine efficacy against COVID-19: A foresight on the host-associated factors
Priyanka, & Choudhary, O. P. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.11.021 · Cited by 20
Yuan, X., Li, C., Zhao, K., & Xu, X. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052447 · Cited by 23
The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data
Li, Z., Liu, X., Liu, M., Wu, Z., Liu, Y., Li, W., Liu, M., Wang, X., Gao, B., Luo, Y., et al. (2021) · Vaccines · doi:10.3390/vaccines9111328 · Cited by 20
Comprehensive Review on Molnupiravir in COVID-19: A Novel Promising Antiviral to Combat the Pandemic
Khiali, S., Khani, E., Rouy, S. B., & Entezari‐Maleki, T. (2022) · Future Microbiology · doi:10.2217/fmb-2021-0252 · Cited by 20
Opt-out policy and its improvements promote COVID-19 vaccinations
Liu, X., Zhao, N., Li, S., & Zheng, R. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.115120 · Cited by 21
Limonta, D., Dyna-Dagman, L., Branton, W. G., Mancinelli, V., Makio, T., Wozniak, R. W., Power, C., & Hobman, T. C. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00491-21 · Cited by 21
Amereh, F., Negahban‐Azar, M., Isazadeh, S., Dabiri, H., Masihi, N., Jahangiri‐rad, M., & Rafiee, M. (2021) · Pathogens · doi:10.3390/pathogens10080946 · Cited by 20
Brockman, M. A., Mwimanzi, F. M., Sang, Y., Ng, K., Agafitei, O., Ennis, S., Lapointe, H. R., Young, L., Umviligihozo, G., Burns, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.17.21253773 · Cited by 19
Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?
Lippi, G., Henry, B. M., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0972 · Cited by 17
Fake news and covid-19: a concern due to the low vaccine coverage in Brazil
Fujita, D. M., Nali, L. H. D. S., Sartori, G. P., Galisteo, A. J., de Andrade, H. F., & Luna, E. J. D. A. (2022) · Saúde e Sociedade · doi:10.1590/s0104-12902022210298 · Cited by 19
Huffman, A., Ong, E., Hur, J., D’Mello, A., Tettelin, H., & He, Y. O. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac190 · Cited by 20
Sobczak, M., & Pawliczak, R. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00525-3 · Cited by 19
Muñoz‐Basagoiti, J., Monteiro, F. L. L., Krumpe, L. R. H., Armario-Nájera, V., Shenoy, S. R., Perez‐Zsolt, D., Westgarth, H. J., Villorbina, G., Bomfim, L., Regué, D. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214561120 · Cited by 19
Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
Baldo, A., Leunda, A., Willemarck, N., & Pauwels, K. (2021) · Vaccines · doi:10.3390/vaccines9050453 · Cited by 19
Recent development of oral vaccines (Review)
Liu, Y., Lam, D. M., Luan, M., Zheng, W., & Ai, H. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12511 · Cited by 18
Song, F., & Bachmann, M. O. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053507 · Cited by 17
Observation on China’s Strategies to Prevent the Resurgence of the COVID-19 Epidemic
Yu, X., Li, N., & Dong, Y. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s305413 · Cited by 19
Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic
Altoé, A. L., Mambriz, A. P. M., Cardozo, D. M., Zacarias, J. M. V., Visentainer, J. E. L., & Bahls, L. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910138 · Cited by 19
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity
Ford, B. N., & Savitz, J. B. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00288-7 · Cited by 18
Kikuchi, K., Anzai, T., & Takahashi, K. (2022) · Journal of Epidemiology · doi:10.2188/jea.je20220186 · Cited by 18
Progress of cGAS-STING signaling in response to SARS-CoV-2 infection
Wu, Y., Zhang, M., Yuan, C., Ma, Z., Li, W., Zhang, Y., Su, L., Xu, J. C., & Liu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1010911 · Cited by 19
Meskell, P., Biesty, L., Dowling, M., Roche, K. F., Meehan, E., Glenton, C., Devane, D., Shepperd, S., Booth, A., Cox, R. J., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000065.pub2 · Cited by 17
A reasoned approach towards administering COVID‐19 vaccines to pregnant women
Pramanick, A., Kanneganti, A., Wong, J. L. J., Li, S. W., Dimri, P. S., Mahyuddin, A. P., Kumar, S., Illanes, S. E., Chan, J. K. Y., Su, L., et al. (2021) · Prenatal Diagnosis · doi:10.1002/pd.5985 · Cited by 19
The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
Zaqout, A., Daghfal, J., Alaqad, I., Hussein, S. A. N., Aldushain, A., Almaslamani, M., Abukhattab, M., & Omrani, A. S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.021 · Cited by 17
A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
Bellier, B., Saura, A., Luján, L. A., Molina, C. R., Luján, H. D., & Klatzmann, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837443 · Cited by 18
Multivalent ACE2 engineering—A promising pathway for advanced coronavirus nanomedicine development
Obeng, E. M., Fianu, I., & Danquah, M. K. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101580 · Cited by 16
Feng, Y., Fan, Y., Luo, X., & Ge, J. (2023) · Building Simulation · doi:10.1007/s12273-023-1060-y · Cited by 17
Bilateral facial palsy after COVID-19 vaccination
Andreozzi, V., d'Arco, B., Pagliano, P., Toriello, A., & Barone, P. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05982-4 · Cited by 17
Alhassan, R. K., Nketiah‐Amponsah, E., Immurana, M., & Abuosi, A. A. (2022) · BMC Public Health · doi:10.1186/s12889-022-13602-1 · Cited by 17
Ebrahim, F. O., Tabal, S., Lamami, Y., Alhudiri, I. M., Meshri, S. E. E., Dwigen, S. M. A., Arfa, R., Alboeshi, A., Alemam, H. A., Abuhtna, F. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122002 · Cited by 19
Singh, P., Ujjainiya, R., Prakash, S., Naushin, S., Sardana, V., Bhatheja, N., Singh, A. P., Barman, J., Kumar, K., Gayali, S., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105419 · Cited by 16
Mahmud, I., Imam, M. H. A., Vinnakota, D., Kheirallah, K. A., Jaber, M. F., Abalkhail, A., Alasqah, I., Alslamah, T., & Kabir, R. (2022) · Vaccines · doi:10.3390/vaccines10071159 · Cited by 17
Ruiz, P. L., Gunnes, N., Gran, J. M., Karlstad, Ø., Selmer, R. M., Dahl, J., Bøås, H., White, R. A., Hofman, A. C., Paulsen, T. H., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.085 · Cited by 17
Zeng, T., Lu, Y., Zhao, Y., Guo, Z., Sun, S., Teng, Z., Tian, M., Wang, J., Li, S., Fan, X., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02542-y · Cited by 17
The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection
Pierro, F. D., & Colombo, M. D. H. P. (2021) · Minerva Medica · doi:10.23736/s0026-4806.21.07487-5 · Cited by 16
Yu, S., Chen, K., Fang, L., Mao, H., Lou, X., Li, C., & Zhang, Y. (2021) · Vaccines · doi:10.3390/vaccines9060588 · Cited by 17
Analysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach
González‐Parra, G. (2021) · Epidemiologia · doi:10.3390/epidemiologia2030021 · Cited by 16
Marazziti, D., Diep, P.-T., Carter, C. S., & Carbone, M. G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220727120646 · Cited by 16
Zhang, Y., Zheng, X., Sheng, W., Liang, H., Zhao, Y., Zhu, X., Yang, R., Zhang, Y., Dong, X., Li, W., et al. (2022) · Vaccines · doi:10.3390/vaccines10081208 · Cited by 16
Nano-Carriers of COVID-19 Vaccines: The Main Pillars of Efficacy
Constantin, C., Pisani, A., Bardi, G., & Neagu, M. T. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0250 · Cited by 15
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment
Zou, H., Yang, Y., Dai, H., Xiong, Y., Wang, J., Lin, L., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732403 · Cited by 16
Webinar Vaksinasi Covid-19 Untuk Meningkatkan Kesadaran Masyarakat
Novita, A., & Ramadhani, N. R. (2021) · Shihatuna Jurnal Pengabdian Kesehatan Masyarakat · doi:10.30829/shihatuna.v1i1.9274 · Cited by 15
Zhang, S., Chen, S., Xiao, G., Zhao, M., Li, J., Dong, W., Hu, J., Yuan, T., Li, Y., & Liu, L. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16786-y · Cited by 15
Williams, L. R., Ferguson, N. M., Donnelly, C. A., & Grassly, N. C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab914 · Cited by 14
Metadata
- Authors
- Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Hodgson, Susanne H
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 21
- Issue
- 2
- Pages
- e26-e35
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC7837315
- OpenAlex
- W3088489318
- Cited by
- 633
- References
- 79
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 52 · 2023: 99 · 2022: 221 · 2021: 221
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- UK Research and Innovation (MC_PC_19055)
- Coalition for Epidemic Preparedness Innovations
- National Institute for Health Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, efficacy endpoints, vaccine development
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Clinical Trials as Topic, Humans, Research Design, Vaccination, Treatment Outcome, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
